查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930156

子宮肌瘤治療市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察，2026-2034年

Uterine Fibroid Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

子宮肌瘤治療市場成長驅動因素

受子宮肌瘤盛行率上升和對非侵入性治療需求增加的推動，全球子宮肌瘤治療市場預計在預測期內將顯著成長。該市場預計在2025年達到 29.7億美元，2026年達到 33.8億美元，到2034年將成長至 97.1億美元，年複合成長率（CAGR）為 16.28%。北美地區憑藉其完善的醫療保健基礎設施、較高的診斷率和創新療法的日益普及，在2025年將以 45.56%的市場佔有率領先。

子宮肌瘤（也稱為子宮平滑肌瘤或肌瘤）是生長於子宮平滑肌和結締組織的良性非癌性腫瘤。雖然有些病例無症狀，但有症狀的子宮肌瘤會引起月經出血、骨盆腔疼痛、貧血、泌尿系統併發症和不孕。久坐不動的生活方式、肥胖、停經延遲和代謝紊亂等因素導致子宮肌瘤的盛行率不斷上升，推動了全球對有效藥物介入的需求。

包括AbbVie Inc.、Neurocrine Biosciences、Sumitomo Pharma在內的市場主要參與者積極開發在研藥物，以滿足日益成長的有效子宮肌瘤治療需求。

市場動態

市場驅動因素

子宮肌瘤負擔日益加重是主要的成長因素，50歲以上女性中，70-80%患有子宮肌瘤，其中許多患者會出現嚴重症狀。女性越來越傾向於選擇保留子宮且不影響生育的藥物治療，而非手術治療。症狀患者數量的增加擴大了目標市場，並促使人們更多地採用新型療法，例如促性腺激素釋放激素促效劑、拮抗劑和選擇性孕激素受體調節劑。

例如，根據NIH（2020）的資料，有症狀的子宮肌瘤可導致異常子宮出血、貧血、骨盆疼痛、泌尿系統問題和不孕，這表明對醫療干預的需求日益成長。

市場限制

嚴重的副作用，例如骨密度下降、潮熱和心血管風險，會降低患者的依從性並縮短治療持續時間。這些安全隱患限制了長期使用，並影響醫生的處方模式，尤其是在育齡婦女中。例如，在 ELARIS UF-1 和 UF-2 試驗（2021年）中，約有 10%的女性因副作用而停止治療。

市場機會

不斷增加的研究計畫創造豐厚的成長機會。與學術機構的合作研究、政府資助以及生物技術公司和製藥公司之間的合作推動下一代療法的開發，包括注射和新型口服 GnRH 拮抗劑。

例如，2022年5月，杜克大學的研究人員合作開發了一種微創且有效的子宮肌瘤注射療法，拓展了治療選擇。

市場挑戰

更嚴格的監管和安全風險對市場成長構成挑戰。女性健康治療需要長期安全性資料，尤其是在生育能力、荷爾蒙平衡和副作用方面。監管力道的加強增加了研發成本和時間，限制了中小型生物製藥公司的競爭。例如，Kissei Pharmaceutical 2022年的GnRH拮抗劑Linzagolix就面臨嚴格的審查流程。

全球市場趨勢

主要市場參與者之間的策略聯盟是一個顯著趨勢，它加速了研發進程，擴大了市場覆蓋範圍，並降低了研發風險。一個值得注意的合作案例是Myovant Sciences和Pfizer於2020年在北美地區成功將 Relugolix 推向市場，加快了市場准入速度，並擴大了患者的用藥範圍。

市場區隔分析

依藥物類別

  • 到2026年，GnRH 促效劑將佔據 54.18%的市場佔有率，廣泛用於快速縮小子宮肌瘤和抑制出血。
  • 由於研發管線的擴展和監管部門的批准，GnRH 拮抗劑預計將實現顯著成長。

依類型

  • 到2026年，由於肌壁間子宮肌瘤的高發生率和嚴重程度，該細分市場將佔據最大的市場佔有率，達到 53.40%。
  • 黏膜下肌瘤預計將以 14.14%的年複合成長率成長。

依給藥途徑

  • 注射劑（腸外給藥）憑藉其長效配方和已證實的療效，預計到2026年將佔據 72.72%的市場佔有率。
  • 口服藥物因其給藥方便和患者依從性高而備受青睞，其年複合成長率預計為 29.5%。

依應用

  • 到2026年，緩解療法將佔據 56.42%的市場佔有率，該療法既能緩解症狀又能改善疾病進程。
  • 疼痛管理療法預計將以 14.92%的年複合成長率成長。

依通路

  • 由於覆蓋面廣，零售藥局和藥局預計在2025年將佔43.1%的市場佔有率。
  • 預計醫院藥局的年複合成長率將達到13.33%。
  • 由於電子商務平台的推廣，線上藥局擴張。

區域展望

北美：預計2025年市場規模將達到13.5億美元，2026年將達到15.4億美元，其中美國就佔14.6億美元。高發病率、先進的醫療基礎設施和策略合作夥伴關係支撐了市場成長。

歐洲：預計到2026年，市場規模將達到 8.7億美元，由於宣傳活動、先進療法和償付政策，預計將成為成長第二快的地區。主要貢獻者為英國、德國和法國。

亞太地區：預計到2026年將達到 7億美元，其中印度佔 9,000萬美元，中國佔 2.5億美元。

拉丁美洲：預計到2026年將達到 1.5億美元，主要得益於醫療保健服務的改善和公眾意識的提高。

中東和非洲：GCC預計到2025年將達到 5,000萬美元。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 關鍵洞察

  • 主要國家和地區的監管環境
  • 主要公司的研發管線分析
  • 主要國家和地區的子宮肌瘤流行病學（2025年）
  • 主要產業趨勢（併購、合作、新產品發表等）

第5章 全球子宮肌瘤治療市場分析、洞察與預測（2021-2034年）

  • 市場分析、洞察與預測 - 依藥物類別
    • GnRH 拮抗劑
    • GnRH 促效劑
    • 其他
  • 市場分析、洞察與預測 - 依類型
    • 肌肉注射子宮肌瘤
    • 黏膜下肌瘤
    • 其他
  • 市場分析、洞察與預測 - 依給藥途徑
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測 - 依應用
    • 狹窄
    • 疼痛管理
    • 其他
  • 市場分析、洞察與預測 - 依通路
    • 醫院藥房
    • 零售藥局和藥局
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美子宮子宮肌瘤治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲子宮肌瘤治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第8章 亞太地區子宮肌瘤治療市場分析、洞察與預測（2021-2034）

  • 依國家/地區
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 亞太其他地區

第9章 拉丁美洲子宮肌瘤治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲子宮肌瘤藥物市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • GCC
    • 南非
    • 中東其他地區非洲

第11章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
  • AbbVie Inc.
  • Sumitomo Pharma Co., Ltd.
  • Pfizer Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • ObsEva SA
  • Neurocrine Biosciences, Inc.
  • TiumBio Co., Ltd.
  • Daewon Pharmaceutical Co., Ltd.
Product Code: FBI114341

Growth Factors of uterine fibroid drugs Market

The global uterine fibroid drugs market is projected to witness significant growth during the forecast period, driven by rising prevalence of uterine fibroids and increasing demand for non-invasive therapeutic options. The market was valued at USD 2.97 billion in 2025, projected to reach USD 3.38 billion in 2026, and is expected to grow to USD 9.71 billion by 2034, exhibiting a CAGR of 16.28%. North America dominated the market in 2025 with a 45.56% share, attributed to robust healthcare infrastructure, high diagnosis rates, and increasing adoption of innovative therapies.

Uterine fibroids, also known as leiomyomas or myomas, are benign, non-cancerous growths of the uterine smooth muscle and connective tissue. While some cases remain asymptomatic, symptomatic fibroids can cause heavy menstrual bleeding, pelvic pain, anemia, urinary complications, and fertility issues. Factors such as sedentary lifestyle, obesity, delayed menopause, and metabolic disorders are contributing to the rising prevalence of uterine fibroids, boosting the global demand for effective pharmacological interventions.

Key players in the market, including AbbVie Inc., Neurocrine Biosciences, and Sumitomo Pharma, are actively developing pipeline candidates to meet the growing need for effective uterine fibroid treatments.

Market Dynamics

Market Drivers

The rising burden of uterine fibroids is the primary growth driver, affecting up to 70-80% of women by age 50, with a significant proportion experiencing severe symptoms. Women increasingly prefer uterus-preserving and fertility-friendly drug therapies over surgical options. The rising symptomatic patient population widens the addressable market, leading to increased adoption of novel therapies such as GnRH agonists, antagonists, and selective progesterone receptor modulators.

For example, according to the NIH (2020), symptomatic uterine fibroids can cause abnormal uterine bleeding, anemia, pelvic pain, urinary issues, and infertility, highlighting the growing demand for medical interventions.

Market Restraints

Severe adverse effects such as bone density loss, hot flashes, and cardiovascular risks can reduce patient adherence and limit treatment duration. These safety concerns restrict long-term usage and influence physicians' prescribing patterns, particularly for women of reproductive age. For instance, in the ELARIS UF-1 and UF-2 trials (2021), approximately 10% of women discontinued treatment due to adverse reactions.

Market Opportunities

Increasing research initiatives are creating lucrative growth opportunities. Academic collaborations, government funding, and biotech-pharma partnerships are driving the development of next-generation therapies, including injectable alternatives and novel oral GnRH antagonists.

For instance, in May 2022, researchers at Duke University collaborated to develop a minimally invasive, effective injectable therapy for uterine fibroids, expanding treatment options.

Market Challenges

Regulatory stringency and safety risks pose challenges to market growth. Women's health therapies require long-term safety data, especially regarding fertility, hormonal balance, and adverse effects. Regulatory scrutiny increases development costs and timelines, limiting smaller biopharma firms' ability to compete. For example, Kissei Pharmaceutical (2022) faced rigorous review processes for its GnRH antagonist, Linzagolix.

Global Market Trends

A prominent trend is strategic collaborations among key market players, which accelerates R&D, expands market reach, and mitigates development risks. Notable collaborations include Myovant Sciences and Pfizer (2020) for commercialization of relugolix in North America, enabling faster market access and expanded patient reach.

Segmentation Analysis

By Drug Class:

  • GnRH agonists dominated with a 54.18% share in 2026, widely adopted for rapid fibroid shrinkage and bleeding control.
  • GnRH antagonists are expected to grow significantly due to expanding pipelines and regulatory approvals.

By Type:

  • Intramural fibroids segment captured the largest share with 53.40% in 2026, due to high prevalence and symptom severity.
  • Submucosal fibroids are projected to grow at 14.14% CAGR.

By Route of Administration:

  • Parenteral (injectables) segment held 72.72% share in 2026, favored for sustained-release formulations and proven efficacy.
  • Oral drugs are growing at 29.5% CAGR, offering ease of administration and better adherence.

By Application:

  • Shrinkage segment dominated with a 56.42% share in 2026, providing both symptomatic relief and disease modification.
  • Pain management segment is projected to grow at 14.92% CAGR.

By Distribution Channel:

  • Retail pharmacies & drug stores held a 43.1% share in 2025, due to wide accessibility.
  • Hospital pharmacies are projected to grow at 13.33% CAGR.
  • Online pharmacies are expanding, driven by e-commerce platforms.

Regional Outlook

North America: Market valued at USD 1.35 billion in 2025, projected to USD 1.54 billion in 2026, with the U.S. alone reaching USD 1.46 billion. Growth is supported by high prevalence, advanced healthcare infrastructure, and strategic collaborations.

Europe: Market estimated at USD 0.87 billion in 2026, second-highest growth due to awareness programs, advanced therapies, and reimbursement policies. Major contributors include the U.K., Germany, and France.

Asia Pacific: Market projected to reach USD 0.7 billion in 2026, with India at USD 0.09 billion and China at USD 0.25 billion.

Latin America: Estimated at USD 0.15 billion in 2026, driven by improving healthcare access and awareness.

Middle East & Africa: GCC countries estimated at USD 0.05 billion in 2025.

Competitive Landscape

The market is semi-consolidated, dominated by AbbVie, Neurocrine Biosciences, Sumitomo Pharma, and Pfizer. Strategic activities include R&D investments, collaborations, and patent filings to expand their global presence. For instance, in June 2025, Altin Biosciences received a Notice of Allowance for its lead drug candidate ABC-105/ABC-205 for non-hormonal treatment of uterine fibroids. Other players include Kissei Pharmaceutical, ObsEva SA, and TiumBio.

Key Industry Developments

  • October 2025: Knight Therapeutics relaunched MYFEMBREE in Canada for heavy menstrual bleeding associated with uterine fibroids.
  • October 2025: Searchlight Pharma secured Canadian rights for Linzagolix.
  • February 2025: Kissei Pharmaceutical submitted NDA for Linzagolix in Japan.
  • December 2024: Theramex received European Commission approval for extended Yselty indication.

Conclusion

The global uterine fibroid drugs market is set to grow from USD 2.97 billion in 2025 to USD 9.71 billion by 2034, at a CAGR of 16.28%, driven by increasing prevalence, technological innovation, and expanding treatment options. North America leads due to robust healthcare infrastructure, while emerging markets offer growth potential. Strategic collaborations, R&D investments, and increasing adoption of oral and injectable therapies are expected to further enhance market growth, offering patients effective, non-surgical management of uterine fibroids worldwide.

Segmentation By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Region

By Drug Class * GnRH Antagonists

  • GnRH Agonists
  • Others

By Type * Intramural Fibroid

  • Submucosal Fibroid
  • Others

By Route of Administration * Oral

  • Parenteral

By Application * Shrinkage

  • Pain Management
  • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Geography * North America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Type, Route of Administration, Application, Distribution Channel, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (Drug Class, Type, Route of Administration, Application, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Epidemology of Uterine Fibroids, By Key Countries/ Regions, 2025
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. GnRH Antagonists
    • 5.1.2. GnRH Agonists
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Intramural Fibroid
    • 5.2.2. Submucosal Fibroid
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Application
    • 5.4.1. Shrinkage
    • 5.4.2. Pain Management
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies & Drug Stores
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. GnRH Antagonists
    • 6.1.2. GnRH Agonists
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Intramural Fibroid
    • 6.2.2. Submucosal Fibroid
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Application
    • 6.4.1. Shrinkage
    • 6.4.2. Pain Management
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies & Drug Stores
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. GnRH Antagonists
    • 7.1.2. GnRH Agonists
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Intramural Fibroid
    • 7.2.2. Submucosal Fibroid
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Application
    • 7.4.1. Shrinkage
    • 7.4.2. Pain Management
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies & Drug Stores
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. GnRH Antagonists
    • 8.1.2. GnRH Agonists
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Intramural Fibroid
    • 8.2.2. Submucosal Fibroid
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Application
    • 8.4.1. Shrinkage
    • 8.4.2. Pain Management
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies & Drug Stores
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Southeast Asia
    • 8.6.5. Australia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. GnRH Antagonists
    • 9.1.2. GnRH Agonists
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Intramural Fibroid
    • 9.2.2. Submucosal Fibroid
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Application
    • 9.4.1. Shrinkage
    • 9.4.2. Pain Management
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies & Drug Stores
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Uterine Fibroid Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. GnRH Antagonists
    • 10.1.2. GnRH Agonists
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. Intramural Fibroid
    • 10.2.2. Submucosal Fibroid
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Application
    • 10.4.1. Shrinkage
    • 10.4.2. Pain Management
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies & Drug Stores
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. AbbVie Inc.
    • 11.2.2. Sumitomo Pharma Co., Ltd.
    • 11.2.3. Pfizer Inc.
    • 11.2.4. Kissei Pharmaceutical Co., Ltd.
    • 11.2.5. ObsEva SA
    • 11.2.6. Neurocrine Biosciences, Inc.
    • 11.2.7. TiumBio Co., Ltd.
    • 11.2.8. Daewon Pharmaceutical Co., Ltd.

List of Tables

  • Table 1: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 3: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 4: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 5: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 8: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 09: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 10: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 11: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 15: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 16: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 17: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 21: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 22: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 23: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 27: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 28: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2033
  • Table 29: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Type 2021-2034
  • Table 33: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Route of Adminstration 2021-2034
  • Table 34: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 35: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Uterine Fibroid Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Uterine Fibroid Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Uterine Fibroid Drugs Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025 & 2034
  • Figure 5: Global Uterine Fibroid Drugs Market Value Share (%), by Application, 2025 & 2034
  • Figure 6: Global Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Uterine Fibroid Drugs Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 11: North America Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 12: North America Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 13: North America Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 14: North America Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 15: North America Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 16: North America Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Uterine Fibroid Drugs Market Value (USD billion), by Country, 2025 & 2034
  • Figure 19: North America Uterine Fibroid Drugs Market Value Share (%), by Country, 2025
  • Figure 20: Europe Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 21: Europe Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 22: Europe Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 23: Europe Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 24: Europe Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 25: Europe Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 26: Europe Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 27: Europe Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 28: Europe Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 34: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 35: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 36: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 37: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 38: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 39: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 40: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 44: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 45: Latin America Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 46: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 47: Latin America Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 48: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 49: Latin America Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 50: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 51: Latin America Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 52: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 57: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Drug Class, 2025
  • Figure 58: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Type 2025 & 2034
  • Figure 59: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Type 2025
  • Figure 60: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Route of Administration 2025 & 2034
  • Figure 61: Middle East & Africaa Uterine Fibroid Drugs Market Value Share (%), by Route of Administration 2025
  • Figure 62: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Application, 2025 & 2034
  • Figure 63: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Application, 2025
  • Figure 64: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Uterine Fibroid Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Uterine Fibroid Drugs Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 68: Global Uterine Fibroid Drugs Market Share (%), by Company, 2025